Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.

标题
Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 15_suppl, Pages e21182-e21182
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2018-09-05
DOI
10.1200/jco.2018.36.15_suppl.e21182

向作者/读者发起求助以获取更多资源

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now